


# IOVANCE

## BIO THER A P E U T I C S

ADVANCING IMMUNO-ONCOLOGY

**Corporate Presentation**

August 2019



# Forward Looking Statements

This presentation contains “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”). We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. The forward-looking statements include, but are not limited to, risks and uncertainties relating to the success, timing, projected enrollment, manufacturing capabilities, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates (including both Company-sponsored and collaborator-sponsored trials in the U.S. and Europe), such as statements regarding the timing of initiation and completion of these trials or cohorts within these trials; the timing of, and our ability to, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, including those product candidates that have been granted breakthrough therapy designation (“BTD”) or regenerative medicine advanced therapy designation (“RMAT”) by the FDA; the strength of our product pipeline; the successful implementation of our research and development programs and collaborations; the success of our manufacturing, license or development agreements; the acceptance by the market of the our product candidates, if approved; our ability to obtain tax incentives and credits; and other factors, including general economic conditions and regulatory developments, not within the our control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: the FDA may not agree with our interpretation of the results of its clinical trials; later developments with the FDA that may be inconsistent with already completed FDA interactions; preliminary clinical results, including efficacy and safety results, from ongoing clinical trials may not be reflected in the final analyses of these trials, including new cohorts within these trials; the results obtained in our ongoing clinical trials, such as the studies and trials referred to in this presentation, may not be indicative of results obtained in future clinical trials or supportive of product approval; regulatory authorities may potentially delay the timing of FDA or other regulatory authority approval of, or other action with respect to, our product candidates (specifically, our description of FDA interactions are subject to FDA’s interpretation, as well as FDA’s authority to request new or additional information); our ability to address FDA or other regulatory authority requirements relating to its clinical programs and registrational plans, such requirements including, but not limited to, clinical and safety requirements as well as manufacturing and control requirements; risks related to our accelerated FDA review designations, including BTD and RMAT and our ability to benefit from such designations; our ability to obtain and maintain intellectual property rights relating to its product pipeline; and the potential reimbursement of our product candidates by payors, if approved.

For more detailed information about the risks and uncertainties that could cause actual results to differ materially from those implied by, or anticipated in, these forward-looking statements, please refer to the Risk Factors section of the Company’s Annual Report on Form 10-K and subsequent updates that may be contained in the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K on file with the SEC. Forward-looking statements speak only as to the date they are made. Except as required by law, we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward looking statements are made. This presentation does not constitute an offer to sell or buy securities, and no offer or sale will be made in any state or jurisdiction in which such offer or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

# Leveraging Tumor Infiltrating Lymphocyte (TIL) to Address Unmet Need

## Discovery

**2011**

**TIL therapy** conducted by Steven Rosenberg/NCI published results showing: **56% ORR<sup>(1)</sup>** and **24% CR** rate in melanoma patients, with durable CRs as an early line therapy<sup>(2)</sup>

## Manufacturing Development, Clinical Program Establishment

**2015**

**FDA Orphan Drug Designation** for lifileucel in malignant melanoma

**2016**

**First patient dosed** for Gen 1 lifileucel in melanoma

**Gen 2 manufacturing** developed and transferred to CMOs

**2017**

Efficacy data from **Gen 2 proprietary, centralized and commercial process** presented

**Head & Neck and Cervical** studies began

**FDA Fast Track** designation for lifileucel in melanoma received

**Partnership with MD Anderson** on multiple solid tumors

Partnership with Ohio State University for PBL in **hematological malignancies**

**2018**

**European sites** activated for Melanoma & Cervical

**FDA RMAT designation** for lifileucel in advanced melanoma received

**FDA End-of-Phase 2 meeting** for lifileucel held

Lifileucel Cohort 2 clinical data showed **38% ORR in 47 patients**, Median DOR: 6.4 months, DCR: 77% in with average 3.3 prior lines of therapy

Two rounds of financing conducted: **over \$425 mil raised**

**2019**

**First patient dosed** for melanoma registrational trial

**FDA Fast Track, Breakthrough Therapy** designation in cervical

Interim data at **ASCO for melanoma showed 38% ORR** and **cervical 44% ORR**

Initiate **building US manufacturing** facility in Philadelphia for commercial supply

**FDA End-of-Phase 2 meeting** for LN-145 for cervical

**File IND** for PBL in CLL

## Commercialization

**2020**

**Complete enrollment** for registrational Cohort 4 in melanoma

**BLA submission** for lifileucel for melanoma

**BLA submission** for LN-145 for cervical

<sup>(1)</sup> Rosenberg, S. A., et al. Clinical Cancer Research, 2011, 17, 4550

<sup>(2)</sup> Goff, S. L. et al. Journal of Clinical Oncology, 2016, 34(20), 2389-2397

# Leveraging Tumor Infiltrating Lymphocyte (TIL) to Address Unmet Need

## Key Highlights

Discovery

2011

TIL therapy conducted by Steven Rosenberg/NCI published results showing: **56% ORR<sup>(1)</sup>** and **24% CR** rate in melanoma patients, with durable CRs as an early line therapy<sup>(2)</sup>

Manufacturing Development, Clinical Program Establishment

2015

FDA Orphan Drug

**2019: Enrolling for melanoma registrational Cohort 4** (fast to market registration plan)

**FDA End-of-Phase 2 meeting for LN-145 for cervical** held

FDA agreed that the ongoing single arm study may be sufficient to support registration of LN-145

**Breakthrough Therapy** designation received in Cervical cancer

**Data update at ASCO:**

Melanoma Cohort 2 showed **38% ORR** (N=66), **DOR not reached**

Cervical showed **44% ORR** (N=27), **DOR not reached**

Commercialization

2020

Complete enrollment for registrational cohort in melanoma

BLA submission for lifileucel

<sup>(1)</sup> Rosenberg, S. A., et al. Clinical Cancer Research, 2011; 17: 4550

<sup>(2)</sup> Goff, S. L. et al. Journal of Clinical Oncology, 2005; 23: 2052



# Investment Highlights

## Leading cell therapy company focused on treatment of solid tumors

Large market opportunity and strong unmet need

Potential to be the first cell therapy approved for solid tumors in melanoma and cervical

Efficient and scalable proprietary manufacturing

Broad platform and wide applications explored through partnerships

- Initial focus in post-checkpoint solid tumors
- Expansion into combinations and earlier lines of therapy
- Four company-sponsored programs in melanoma, cervical, head & neck and basket study in CPI naive

- Accelerated path to approval in melanoma and cervical cancer
- Enrollment on track for pivotal trial for melanoma and BLA filing expected 2H 2020
- Melanoma: RMAT, Orphan Drug, and Fast Track
- Cervical: Breakthrough Therapy designation, Orphan Drug and Fast Track


- U.S. and E.U. capacity with contract manufacturers
- Building Iovance 136,000 sq. ft. manufacturing facility in Philadelphia
- Rapid 22-day Gen 2 manufacturing with >90% success rate
- **200+ patients treated with Iovance proprietary process**

- Investigator-led programs to evaluate additional solid tumors or new combinations
- Touch points with institutions including NIH/NCI, Moffitt Cancer Center, MD Anderson, Roswell Park, Ohio State University, and University of Montreal (CHUM)

# Highly Individualized, Specific, and Potent Attack Against Cancer

Leverages and enhances the body's natural defense against cancer using a patient's own **Tumor Infiltrating Lymphocytes, or TIL**

- **Polyclonal:** Can recognize multiple neoantigens
  - Effective in solid tumors which are heterogeneous
  - Available data in melanoma, cervical, head & neck, and lung cancers
- **Individualized:** TIL of each patient is specific and private with almost no overlap of uCDR3 between patients <sup>(1)</sup>
- **Persistence:** 100% of patients had TIL persisting at Day 42 <sup>(1)</sup>
- **Immunological memory:** Potentially no additional maintenance therapy after infusion
  - Responses seen in both treatment naïve and refractory melanoma patients, including checkpoint refractory
  - Complete responses observed in cervical cancer patients, maintained at 53 and 67 months <sup>(2)</sup>



<sup>(1)</sup> Gontcharova, *et al.*, Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma, AACR 2019, Abstract #LB-069

<sup>(2)</sup> Stevanovic, *et al.*, Treatment of Metastatic Human Papillomavirus-Associated Epithelial Cancers with Adoptive Transfer of Tumor-Infiltrating T Cells, ASCO 2018, Abstract #3004

# Competitive Advantages of TIL in Solid Tumors

CHECKPOINTS	TCR	CAR-T (LIQUID TUMORS)	TIL (SOLID TUMORS)
Target multiple tumor antigens	Target only single tumor antigen	Mainly target only single/surface tumor antigen	Target multiple tumor antigens
Long maintenance period	One-time treatment	One-time treatment	One-time treatment
Utility in several solid tumors	Few solid tumors treated so far	No examples of successful utility in solid tumors	Available data in: melanoma, cervical, head & neck and lung cancers
Potential long-term irreversible toxicities	Potential on-target, off-tissue effects	Potentially immunogenic: cytokine release syndrome	No unexpected off-tissue effects found to date
Off-the-shelf	Autologous	Autologous	Autologous



TIL target a diverse array of cancer antigens; we believe this approach represents a **highly differentiated, customized, and targeted immunotherapy**


# Developed Centralized, Scalable, and Efficient GMP Manufacturing

**EXCISE:** Patient's tumor is removed via surgical resection of a lesion

**EXTRACT:** Tumor is fragmented and placed in media for TIL to leave the tumor and enter media

**EXPAND:** TIL expanded via IL-2 + OKT3 exponentially *ex vivo* to yield  $10^9 - 10^{11}$  TIL

**PREPARE & INFUSE:** Patient receives non-myeloablative lymphodepletion and is infused with their expanded TIL and IL-2



Courier from  
clinical site



Co-culture TIL and  
feeder cells for  
expansion *ex vivo*



Harvest and  
cryopreserved TIL  
infusion product



Courier to clinical  
site for infusion



# Broad, Iovance-Owned IP Around TIL Therapy

## Manufacturing

Seven recently granted or allowed U.S. patents for compositions and methods of treatment in a broad range of cancers relating to its Gen 2 manufacturing process including combinations with PD-1 antibodies:

- U.S. Patent No. 10,166,257
- U.S. Patent No. 10,130,659
- U.S. Patent No. 10,272,113

## Advanced technologies

Patent applications filed for a wide range of TIL technologies including:

- Marrow infiltrating and peripheral blood lymphocyte therapies
- Use of costimulatory molecules in TIL therapy
- Stable and transient genetically-modified TIL therapies
- Patient subpopulations for TIL therapies

# Iovance Commercial Manufacturing Facility



- Build-to-suit custom facility located in the Navy Yard, Philadelphia, PA
- ~136,000 sq. feet
- GMP production is expected to commence in 2022
- IOVA investing \$75M over 3 years
- Significant reduction in COGS expected

Rendering by DIGSAU

# Significant Market Potential in Solid Tumors


**90%**  
**of all cancer cases**  
**are solid tumors**

**1.6M**  
**New cases of solid**  
**tumors in the U.S.<sup>(1)</sup>**

<sup>(1)</sup> <https://seer.cancer.gov>

	Move into earlier line of therapy	
	Deaths <sup>(1)</sup>	New Cases <sup>(1)</sup>
Expand into other indications	Melanoma	91,270
	Cervix Uteri	13,240
	Oral Cavity, Pharynx & Larynx	64,690
	Lung & Bronchus	234,030
	Bladder	81,190
	Breast	268,670
	Pancreatic	55,440
	Brain & Other Nervous System	23,880
	Potential to address unmet need in late lines of treatment	Potential market for early lines in combo with standard of care

# Current Clinical Pipeline and Select Collaboration Studies

	Regimen	Trial	Indication	N	Partner	Phase 1	Phase 2	Pivotal
Company sponsored studies	Lifileucel	C-144-01	Melanoma	164	—	<div></div>		
	LN-145	C-145-04	Cervical cancer	75	—	<div></div>		
	LN-145	C-145-03	Head & neck cancer	47	—	<div></div>		
	Lifileucel + pembrolizumab	IOV-COM-202	Melanoma	48	—	<div></div>		
	LN-145 + pembrolizumab		Head & neck					
Select investigator sponsored proof-of-concept studies	LN-145 + pembrolizumab		Non-small cell lung					
	LN-145		Non-small cell lung					
	MDA TIL	NCT03610490	Ovarian, sarcomas, pancreatic	~54	MD Anderson Cancer Network™	<div></div>		
	LN-145	NCT03449108	Ovarian, sarcomas	~54	MD Anderson Cancer Network™	<div></div>		
	LN-145 + pembrolizumab	NCT03935347	Bladder cancer	12		<div></div>		

\*trial will be expanded to enroll 75-100



# Metastatic Melanoma

# Potential Market for Metastatic Melanoma

- **Estimated 9,320 U.S. patients** deaths due to melanoma in 2018<sup>(1)</sup>
- **Limited options** after progression on checkpoint and BRAF/MEK inhibitors:
  - **6,282 U.S. patients** are on 2<sup>nd</sup> line therapy<sup>(2)</sup>
  - **4,950 U.S. patients** are on 3<sup>rd</sup> and 4<sup>th</sup> line of therapy<sup>(2)</sup>
  - **TIL is available as a 2<sup>nd</sup> line** for those who are BRAF WT (3<sup>rd</sup> line if BRAF mutant)

## Metastatic Melanoma Facts

**282k** New Cases WW  
each year<sup>(4)</sup>

**62k** Deaths WW  
each year<sup>(4)</sup>

**91k** Diagnoses in U.S.  
each year<sup>(1)</sup>

**9k** Deaths in U.S.  
each year<sup>(1)</sup>

Available care:  
**immuno-  
therapy**  
as first line  
option

**BRAF  
positive**  
patients treated  
with BRAF/MEK  
inhibitors

**ORR 4-10%**  
Retreatment with  
checkpoint inhibitors  
or chemotherapy  
post progression on  
anti-PD1 and  
BRAF/MEK<sup>(3)</sup>

<sup>(1)</sup> <https://seer.cancer.gov>


<sup>(2)</sup> Decision Resources Group – Disease Landscape and Forecast for Malignant Melanoma- Reprinted with permission. ©2018 DR/Decision Resources, LLC

<sup>(3)</sup> Keynote-37 Trial Results

<sup>(4)</sup> Global Burden of Disease Cancer Collaboration, Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018 Nov 1;4(11):1553-1568. doi: 10.1001/jamaoncol.2018.2706

# C-144-01: Phase 2 Study Design

Phase 2, multicenter study to assess the efficacy and safety of autologous **Tumor Infiltrating Lymphocytes (lifileucel)** for treatment of patients with **metastatic melanoma** (NCT02360579)



## Endpoints:

- Primary: Efficacy defined as investigator ORR
- Secondary: Safety and efficacy

## Study Updates:

- October 2018: Cohort 2 data for 47 patients at SITC
- March 2019: Cohort 4 (pivotal trial) first patient dosed
- May 2019: Topline data on 55 patients in ASCO abstract
- June 2019: Full Cohort 2 data on 66 patients presented at ASCO

# C-144-01: Cohort 2 Update at ASCO 2019

COHORT 2

## Key inclusion criteria:

- Measurable metastatic melanoma and  $\geq 1$  lesion resectable for TIL generation
- Progression on at least one prior line of systemic therapy including immune checkpoint inhibitor or a BRAF or BRAF/MEK
- Age  $\geq 18$
- ECOG PS 0-1

## Endpoints:

- Primary: efficacy defined as ORR by investigator per RECIST 1.1
- Secondary: safety and efficacy

## Study updates:

- Cohort 2 fully enrolled
- Data readout on 47 patients at SITC
- Data readout on 66 patients at ASCO

Baseline Demographics	N=66 (%)
Prior therapies	
Mean # prior therapies	3.3
Anti-PD-1	66 (100)
Anti-CTLA-4	53 (80)
BRAF/MEK	15 (23)
Target lesions sum of diameter (mm)	
Mean (SD)	106 (71)
Min, Max	11, 343
Baseline LDH (U/L)	
Median	244
1-2 times ULN	19 (29)
> 2 times ULN	8 (12)
Number of target & non-target lesions (at baseline)	
>3	51 (77)
Mean	6




# Adverse Events Tend to be Early and Transient

Frequency of AEs over time is reflective of potential benefit of one time treatment with lifileucel

Lifileucel Treatment-Emergent Adverse Events (≥ 30%)

PREFERRED TERM	Cohort 2, N=66		
	Any Grade, n (%)	Grade 3/4, n (%)	Grade 5, n (%)
Number of patients reporting at least one Treatment-Emergent AE**	65 (98.5)	63 (95.5)	2 (3.0)
Thrombocytopenia	59 (89.4)	53 (80.3)	0
Chills	52 (78.8)	4 ( 6.1)	0
Anemia	44 (66.7)	36 (54.5)	0
Pyrexia	39 (59.1)	11 (16.7)	0
Febrile neutropenia	36 (54.5)	35 (53.0)	0
Neutropenia	36 (54.5)	25 (37.9)	0
Hypophosphatemia	29 (43.9)	22 (33.3)	0
Fatigue	27 (40.9)	1 (1.5)	0
Leukopenia	27 (40.9)	22 (33.3)	0
Hypotension	23 (34.8)	7 (10.6)	0
Tachycardia	22 (33.3)	1 ( 1.5)	0
Lymphopenia	21 (31.8)	19 (28.8)	0

Adverse Events Over Time



\*\*Treatment-Emergent Adverse Events refer to all AEs starting on or after the first dose date of TIL up to 30 days. Patients with multiple events for a given preferred term are counted only once using the maximum grade under each preferred term. Safety terms which describe the same medical condition were combined.

\*The number of AEs is cumulative and represent the total number of patients dosed

# Potentially Efficacious Treatment for Patients with Limited Options

- In heavily pretreated metastatic melanoma patients (3.3 mean prior therapies)
  - **ORR 38%**
  - **DCR 80%**
  - **Median DOR has not been reached**
    - Median follow-up 8.8 months
  - Patients with PD-L1 negative status (TPS<5%) were among responders
  - Mean TIL cells infused: **27.3 x 10<sup>9</sup>**
  - Median number of IL-2 doses: 5.5


## Responses

N=66 (%)

Objective Response Rate	25 (38%)
Complete Response	2 (3%)
Partial Response	23 (35%)
Stable Disease	28 (42%)
Progressive Disease	9 (14%)
Non-Evaluable	4 (6%)
Disease Control Rate	53 (80%)

# Responders Previously Progressed on Checkpoint Inhibitors

Lifileucel time to response and current duration of for evaluable patients (partial response or better)




BOR is best overall response on prior anti-PD-1 immunotherapy

# TIL Therapy Provides Deep Responses

- 81% of patients had a reduction in tumor burden
- Mean Time to response 1.9 months (range 1.3-5.6)
- All assessments are by RECIST 1.1
- Responses are deep – nearly all responders are greater than 30%

## Lifileucel best overall response rate<sup>(1)</sup>



(1) Three subjects had no post TIL disease assessment due to early death; one subject had no post-TIL disease assessment due to new cancer therapy. For subject #30, 100% change from baseline is displayed for the CR visit involved lymph nodes.



# Cohort 4 is a Pivotal Single-Arm Registrational Trial

## Key inclusion criteria:

- Measurable metastatic melanoma and  $\geq 1$  lesion resectable for TIL generation
- Progression on at least one prior line of systemic therapy including immune checkpoint inhibitor and if BRAF V600 mutation positive, BRAF or BRAF/MEK targeted therapy

## Endpoints:

- Primary: efficacy defined as ORR by BIRC
- Secondary: safety and efficacy

## Study updates:

- Confirmed with FDA that a randomized Phase 3 study is not feasible in advanced melanoma post-CPI
- FDA has acknowledged acceptability of single-arm data for registration
- March 2019: First patient dosed

## Cohort 4 (Pivotal):

Cryopreserved TIL  
product (Gen 2)  
N=75


Per FDA interaction

# Late Stage (2L/3L) Melanoma Treatment Development Efforts

## 2L/3L melanoma treatment has no current standard of care

	Agent	ORR % (N)	Current Development Status	Prior Lines of Tx	Patient Characteristics
Combination with anti-PD-1	<b>Checkpoints</b>				
	LAG-3 +nivo (BMS)	12% (N=61) <sup>(1)</sup>	Multiple 1L studies	1+	All comers, ECOG ≤2 • LAG-3 expression ≥1% (N=33) ORR=18%; • LAG-3 expression <1% (N=22) ORR=5%
	<b>TLR9 agonists, HDAC</b>				
	IMO-2125 (Idera) + ipi	29% (N=34) <sup>(2)</sup>	Phase 3, post-PD-1 melanoma ILLUMINATE 204	1-3	ECOG ≤1, intratumoral injection
	CMP-001 (CheckMate) + pembro	22% (N=69) <sup>(3)</sup>	Phase 1b	1+	ECOG ≤1, intratumoral injection
	SD-101 (Dynavax) + pembro	21% (N=29) <sup>(4)</sup>	Phase 1b/2 (abandoned) <sup>(7)</sup>	1+	ECOG ≤1 intratumoral injection
Single Agent	Entinostat (Syndax) + pembro	19% (N=53) <sup>(5)</sup>	ENCORE 601	1+	ECOG ≤1
	<b>Checkpoints</b>				
	TIGIT, TIM-3	Unknown	Phase 1/2		
	<b>Cytokines</b>				
	HD IL-2	8% (N=9) <sup>(6)</sup>		1+	HD IL-2 post PD-1
	<b>Other</b>				
	<b>TIL</b>	<b>38% (N=66)</b>	<b>Phase 2, continuing to enroll pivotal trial</b>	<b>3.3</b>	<b>All post-anti-PD1</b>

# Cervical Cancer



# Potential Market for Cervical Cancer

*“TIL immunotherapy with LN-145 is literally redefining what is treatable and potentially curable in advanced metastatic chemo-refractory cervical cancer. Patients who only two years ago would be facing hospice as their only alternative now have access to this potentially life extending new treatment. This is the most exciting news in this field in decades.”*

Amir Jazaeri, M.D.

Director of the Gynecologic Cancer Immunotherapy Program in the Department of Gynecologic Oncology and Reproductive Medicine at MD Anderson

## Cervical Cancer Facts

**511k** New Cases WW  
each year<sup>(1)</sup>

**247k** Deaths WW  
each year<sup>(1)</sup>

**13k** Diagnoses in U.S.  
each year<sup>(2)</sup>

**4k** Deaths in U.S.  
each year<sup>(2)</sup>

Available care:  
**Chemo-  
therapy**  
as first line  
option

For PD-L1 +  
patients, post-  
chemo receiving  
Keytruda<sup>(3)</sup>  
**ORR 14.3%**

**Available  
Care** for  
chemotherapy in  
2L metastatic  
cervical patients  
**4.5-13%**<sup>(4)(5)</sup>

<sup>(1)</sup> Global Burden of Disease Cancer Collaboration, Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018 Nov 1;4(11):1553-1568. doi: 10.1001/jamaoncol.2018.2706

<sup>(2)</sup> <https://seer.cancer.gov/>

<sup>(3)</sup> [https://www.merck.com/product/usa/pi\\_circulars/k/keytruda/keytruda\\_pi.pdf](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)


<sup>(4)</sup> Schilder et al., Gynecologic Oncology 2005

<sup>(5)</sup> Weiss, et al., A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group Study



# C-145-04: Pivotal Phase 2 Trial in Cervical Cancer

Phase 2, multicenter study to evaluate the efficacy and safety of autologous **Tumor Infiltrating Lymphocytes (LN-145)** in patients with **recurrent, metastatic or persistent cervical carcinoma** (NCT03108495)



## Endpoints:

- Primary: ORR as determined by BIRC
- Secondary: safety and efficacy

## Study updates:

- March 2019: Fast Track designation
- May 2019: Breakthrough Therapy designation
- June 2019: Longer follow-up presented at ASCO
- June 2019: FDA EOP2 held-existing study may be sufficient to support registration of LN-145
- July 2019: study expanded to enroll a total of 75 patients

# LN-145 in Cervical Cancer Interim Update at ASCO 2019

## Key inclusion criteria:

- Recurrent, metastatic or persistent cervical carcinoma with 1 prior therapy
- Age  $\geq 18$

## Endpoints:

- Primary: efficacy defined as ORR by investigator per RECIST 1.1
- Secondary: safety and efficacy

## Study updates:

- Protocol amended to increase total to 75 patients
- ORR as determined by Blinded Independent Review Committee (BIRC)
- Fast Track and Breakthrough Therapy designation received
- EOP2 meeting held with FDA

Baseline	
Demographics	N=27 (%)
Prior therapies	
Mean # prior therapies	2.4
Platinum-based	27 (100)
Taxane	26 (96)
Anti-VEGF	22 (82)
PD-1/PD-L1	4 (15%)
Target lesions sum of diameter (mm)	
Mean (SD)	61 (38)
Min, Max	10, 165
Histologic Cell Type, n (%)	
Squamous Cell Carcinoma	12 (44)
Adenocarcinoma	12 (44)
Adenosquamous Carcinoma	3 (11)
Number of target & non-target lesions (at baseline)	
>3	17 (63)
Mean (min,max)	4 (1,9)


# Adverse Events Tend to be Early and Transient

Frequency of AEs over time is reflective of potential benefit of one time treatment with TIL (LN-145)

PREFERRED TERM	N=27		
	Any Grade, n (%)	Grade 3/4, n (%)	Grade 5, n (%)
Number of patients reporting at least one Treatment-Emergent AE**	27 (100)	26 (96.3)	0
Chills	21 (77.8)	0	0
Anemia	15 (55.6)	15 (55.6)	0
Diarrhea	14 (51.9)	2 (7.4)	0
Pyrexia	14 (51.9)	1 (3.7)	0
Thrombocytopenia	14 (51.9)	12 (44.4)	0
Neutropenia	11 (40.7)	8 (29.6)	0
Vomiting	11 (40.7)	1 (3.7)	0
Hypotension	10 (37.0)	4 (14.8)	0
Dyspnea	9 (33.3)	1 (3.7)	0
Febrile neutropenia	9 (33.3)	8 (29.6)	0
Hypoxia	9 (33.3)	3 (11.1)	0
Leukopenia	9 (33.3)	6 (22.2)	0
Hypomagnesemia	8 (29.6)	0	0
Sinus tachycardia	8 (29.6)	0	0

\*\*Treatment-Emergent Adverse Events refer to all AEs starting on or after the first dose date of TIL up to 30 days. Patients with multiple events for a given preferred term are counted only once using the maximum grade under each preferred term. Safety terms which describe the same medical condition were combined.

\*The number of AEs is cumulative and represent the total number of patients dosed




# Significant Response Observed in Patients with Limited Options

- In heavily pretreated cervical cancer patients (2.4 mean prior therapies)
  - **CR 11%**
  - **ORR 44%**
  - **DCR 85%**
  - **Median DOR has not been reached**
    - Median follow-up 7.4 months
  - Mean TIL cells infused: **28 x 10<sup>9</sup>**
  - Median number of IL-2 doses: 6.0

Responses	N=27 (%)
<b>Objective Response Rate</b>	<b>12 (44%)</b>
Complete Response	3 (11%)
Partial Response	9 (33%)
Stable Disease	11 (41%)
Progressive Disease	4 (15%)
Non-Evaluable	0
Disease Control Rate	23 (85%)

# Responses Observed Early On and Consistent with Melanoma

LN-145 time to response and current duration of for evaluable patients (partial response or better)




- Mean time to first response 1.9 months
- Mean time to best response 2.4 months



# Three Complete Responses Observed with LN-145

- 78% of patients had a reduction in tumor burden
- Mean Time to response 1.9 months
- All assessments are by RECIST 1.1
- Responses are deep – majority of responders are over 30%

## LN-145 best overall response rate




# Development Efforts in Recurrent, Metastatic or Persistent Cervical Carcinoma

Recurrent, metastatic or persistent cervical carcinoma has no current standard of care

Agent	ORR % (N)	Current Dev Status	Prior Line of Tx	Patient Characteristics
<b>Antibody-drug conjugate</b>				
tisotumab vedotin (TV) (Genmab/Seattle Genetics)	22% (N=55) <sup>(1)</sup>	Phase 2	1+	Recurrent or metastatic cervical cancer that progressed on standard therapy (most had received at least two prior therapies), median DOR= 6 months
<b>Anti-PD-1</b>				
AGEN2034 (Agenus)	11% (N=9) <sup>(2)</sup>	Phase 2	1+	Patients must have relapsed after a platinum-containing doublet administered for treatment of advanced disease
cemiplimab (Regeneron)	10% (N=10) <sup>(3)</sup>	Phase 3	2+	Recurrent or metastatic cervical cancer resistant to, or intolerant of, platinum therapy
<b>TKI</b>				
neratinib (Puma Biotechnology)	27% (N=11) <sup>(4)</sup>	Phase 2	2	Metastatic HER2-positive cervical cancer (percentage of HER2+ in cervical cancer is ~3.9%) <sup>(5)</sup>
<b>Cell therapies</b>				
TIL (LN-145)	44% (N=27)	Phase 2	2.4 (mean)	All patients progressed on or after chemotherapy

# TIL in Earlier Lines of Therapy in Combination with SOC

A Phase 2, Multicenter Study of Autologous **Tumor Infiltrating Lymphocytes (lifileucel or LN-145)** in Patients with **Solid Tumors** (NCT03645928)




## Endpoints:

- Primary: ORR and safety
- Secondary: CR rate

## Study updates:

- 16 sites are activated globally
- Sites in the U.S. and additional countries
- **First patient dosed**

# Hematologic Malignancies




# Peripheral Blood Lymphocytes (PBL) for Hematological Indications

## Expand the TIL platform into new indications



- IOV-2001 for post-ibrutinib CLL patients
- IOV-2001 is a non-genetically modified, polyclonal T cell product
- IOV-2001 shows cytotoxicity against autologous tumor cells in leukemia
- Ibrutinib has known to improve proliferative and effector functions of T cells
- Iovance has generated PBL from 50 mL blood of ibrutinib-treated patients with CLL
- A 9 day manufacturing process is optimized and is being transferred to a CMO
- IND filing is planned for 2019



Karyapudi et al., EHA 2019, PF 447



# Research Focus into Next Generation TIL



## Expand the TIL platform into new indications

- Bladder cancer (Roswell Park Cancer Institute)
- IND for PBL in CLL (OSU collaboration)



## Prepare or select more potent TIL

- Use anti-4-1BB, anti-OX40, or other co-stimulants in cocktails in *ex vivo* growth of TIL
  - License to uses of 4-1BB agonists obtained from Moffitt Cancer Center
- PD-1 positive select TIL collaboration with CHUM



## Genetically modify to make a more tumor-reactive TIL

- Collectis TALEN® collaboration
- Phio RNAi collaboration




## Identify biomarkers to find a better TIL product or better patient population

- Genoceia ATLAS™ collaboration

# Iovance Biotherapeutics Global Reach and Scale

Iovance Biotherapeutics has ~125 employees

- Headquartered in San Carlos, CA
- 4 additional offices
- Iovance commercial manufacturing facility in Philadelphia, PA (under construction)



# Well Capitalized in Pursuit of TIL Commercialization

June 30, 2019

In millions (unaudited)

---

Common shares outstanding

124

Preferred shares

6<sup>(1)</sup>

Options

9

Cash, cash equivalents, short-term investments,  
restricted cash

\$410<sup>(2)</sup>

Debt

0

---

(1) Preferred shares are shown on an as-converted basis

(2) Includes Restricted Cash of \$5.5 million

# Achieved and Upcoming Milestones 2019

- ☒ First patient dosed in Cohort 4 for lifileucel in support of registration
- ☒ Present updated data in Cohort 2 for melanoma at ASCO
- ☒ Present data from Gen 2 of cervical study at ASCO
- ☒ Initiate building lovance manufacturing facility
- ☒ Define regulatory path for LN-145 in cervical cancer with FDA
- ☐ Explore therapeutic potential of TIL in other indications
- ☐ File new IND for new manufacturing process and/or new indications

# IOVANCE

B I O T H E R A P E U T I C S

ADVANCING IMMUNO-ONCOLOGY

## Thank you

